{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:41:34Z","timestamp":1791308494585,"version":"4.3.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cca.2019.10.031","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T17:42:18Z","timestamp":1574530938000},"page":"27-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["\u03b1-Galactosidase A\/lysoGb3 ratio as a potential marker for Fabry disease in females"],"prefix":"10.1016","volume":"501","author":[{"given":"G.V.","family":"Baydakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Ilyushkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.O.","family":"Bychkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.V.","family":"Nikitina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0422.\u0410.","family":"Buruleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.Y.","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2019.10.031_b0005","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2019.10.031_b0010","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2019.10.031_b0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.cca.2019.10.031_b0020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.cca.2019.10.031_b0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"1","key":"10.1016\/j.cca.2019.10.031_b0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"12","key":"10.1016\/j.cca.2019.10.031_b0035","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/ijms19123726","article-title":"Mutations in the GLA Gene and LysoGb3: is it really Anderson-Fabry disease?","volume":"9","author":"Duro","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cca.2019.10.031_b0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2019.10.031_b0045","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/mds.27393","article-title":"Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations","volume":"33","author":"Pchelina","year":"2018","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.cca.2019.10.031_b0050","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.cca.2019.10.031_b0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2019.10.031_b0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3343\/alm.2013.33.4.274","article-title":"Analysis of lyso-globotriaosylsphingosine in dried blood spots","volume":"33","author":"Johnson","year":"2013","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.cca.2019.10.031_b0065","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"Fabry disease in females: clinical characteristics and effects of enzyme replacement therapy","author":"Deegan","year":"2006"},{"issue":"1","key":"10.1016\/j.cca.2019.10.031_b0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mayocp.2018.08.009","article-title":"Cost efficacy of alpha-galactosidase A enzyme screening for Fabry disease","volume":"94","author":"Newman","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.cca.2019.10.031_b0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.cca.2019.10.031_b0080","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/ene.13254","article-title":"Screening for Fabry disease in patients with ischaemic stroke at young age: the Italian Project on Stroke in Young Adults","volume":"24","author":"Poli","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.cca.2019.10.031_b0085","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ene.13775","article-title":"Genomic screening of Fabry disease in young stroke patients: the Taiwan experience and a review of the literature","volume":"26","author":"Lee","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.cca.2019.10.031_b0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.cca.2019.10.031_b0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","volume":"41","author":"Burlina","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.cca.2019.10.031_b0100","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.cca.2019.10.031_b0105","doi-asserted-by":"crossref","first-page":"e0193550","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cca.2019.10.031_b0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: Lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"4","key":"10.1016\/j.cca.2019.10.031_b0115","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.cca.2019.10.031_b0120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2017.12.431","article-title":"Rapid screening for lipid storage disorders using biochemical markers. Expert center data and review of the literature","volume":"123","author":"Voorink-Moret","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2019.10.031_b0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.01.018","article-title":"Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation","volume":"466","author":"Auray-Blais","year":"2017","journal-title":"Clin. Chim. Acta."},{"issue":"2","key":"10.1016\/j.cca.2019.10.031_b0130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2019.10.031_b0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease","volume":"180","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119320960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119320960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:49:22Z","timestamp":1757861362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119320960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":27,"alternative-id":["S0009898119320960"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.10.031","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b1-Galactosidase A\/lysoGb3 ratio as a potential marker for Fabry disease in females","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}